Bryce Poynt Consulting

07/04/2025

🇺🇸✨ Happy 4th of July!
Today we celebrate freedom, resilience, and the messy, beautiful work of building a better future—together.
Whether you're lighting up the grill or watching the sky sparkle tonight, here’s to connection, community, and the courage to keep moving forward.

Stay safe, stay grateful, and don’t forget the sunscreen. ☀️🎆

07/03/2025

07/01/2025

:

🚨 Now Hiring: Sr. MES Engineer
📍 Biotech | Pharma | Digital Manufacturing

We’re supporting a confidential life sciences client seeking a Senior MES Engineer to help modernize regulated manufacturing systems. Think eBRs, GMP compliance, and real-time digital ex*****on.

💡 If you’re experienced with PAS-X, Syncade, PharmaSuite, or Ignition MES — let’s talk.

🔬 Not hiring right now? Keep Bryce Poynt Consulting on your radar — still deep in biotech + pharma talent strategy.

📩 DM to connect.

09/04/2024

12/25/2023

Merry Christmas!

May the festive spirit inspire new beginnings, and the coming year bring fresh opportunities for growth and success.

Warmest wishes from Bryce Poynt Consulting!

11/23/2023

Gratitude is our favorite recipe for a happy Thanksgiving!

Today, let's pause and cherish the abundance of big and little blessings that make our journey extraordinary. Wishing you a day filled with warmth, joy, and gratitude.

Happy Thanksgiving from all of us at Bryce Poynt Consulting! 🧡

11/03/2023

Seize the Chance to Make Your Mark in Renewable Energy Finance: Join Our Startup's Journey to Success!

Explore Our Current Job Opportunities:

Director of Accounting and Finance
Accounting Manager
Accounting Associate
Staff Accountant

Eager to be part of our journey? Share your resume with us at [email protected] and let's power the future together!

09/30/2023

Friday: A Reminder of the Rewarding Harvest from Your Week's Dedication.

09/04/2023

From all of us at Bryce Poynt Consulting we salute the dedication and hard work of our team and workers everywhere.
Wishing everyone a rejuvenating Labor Day!

08/16/2023

Jasper Therapeutics hits a crucial milestone by dosing its first patient in a Phase 1 trial, bringing revolutionary hematopoietic stem cell transplantation closer to reality. Their innovative approach aims to enhance safety and effectiveness in the transplantation process, potentially transforming treatments for various blood disorders and cancers. This achievement marks a significant leap towards reshaping the landscape of regenerative medicine.

Last week, we announced the first patient dosed in a Phase 1 study in low-risk myelodysplastic syndrome (LR-MDS). We’re excited to continue exploring briquilimab’s therapeutic potential in targeting c-Kit for patients with LR-MDS. Read the full announcement: https://ir.jaspertherapeutics.com/news-releases/news-release-details/jasper-therapeutics-announces-first-patient-dosed-phase-1-trial